{
    "clinical_study": {
        "@rank": "102669", 
        "acronym": "RANIA", 
        "arm_group": [
            {
                "arm_group_label": "Raltegravir plus Nevirapine plus Lamivudine", 
                "arm_group_type": "Experimental", 
                "description": "Raltegravir 400 mg oral twice daily plus nevirapine 200 mg oral twice daily plus lamivudine 150 mg oral twice daily for 96 weeks"
            }, 
            {
                "arm_group_label": "Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate changes in renal function, efficacy, and safety when switching from a\n      combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r)\n      to a combination of raltegravir (MK-0518) plus nevirapine plus lamivudine in human\n      immunodeficiency virus (HIV)-1 participants with suppressed viremia and impaired renal\n      function (MK-0518-284)"
        }, 
        "brief_title": "Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, or non-pregnant, non-breastfeeding female\n\n          -  No previous history of virological failure\n\n          -  No previous exposure to non-nucleoside reverse transcriptase inhibitors or integrase\n             inhibitors\n\n          -  No previous history of intolerance to lamivudine\n\n          -  At least 2 documented plasma HIV-1 RNA <50 copies/mL and no HIV-1 >50 copies/mL in\n             the 12 months before screening\n\n          -  Receiving the same protease inhibitor/ritonavir plus tenofovir/emtricitabine\n             combination for at least the 6 months before screening\n\n          -  Has no major International Antiviral Society (IAS)-USA mutations on genotype testing\n             performed before starting antiretroviral treatment\n\n          -  Sexually-active participants and their partners of child-bearing potential agree to\n             use a medically acceptable method of contraception from 2 weeks before Day 1 and for\n             at least 6 months after the last dose of study drug (postmenopausal women are not\n             required to use contraception; sexually-active male participants with a female\n             partner of child-bearing potential must provide written informed consent to\n             information regarding any pregnancy)\n\n        Exclusion Criteria:\n\n          -  Positive for hepatitis B surface antigen (HBsAg+) or anticipated need for hepatitis C\n             virus treatment\n\n          -  Liver cirrhosis\n\n          -  Allergy or sensitivity to the investigational product or excipients\n\n          -  Female participant who is nursing\n\n          -  Female participant who is pregnant or intends to become pregnant\n\n          -  Has an active Acquired Immunodeficiency Syndrome (AIDS)-defining event except stable\n             Kaposi Sarcoma or HIV Wasting Syndrome\n\n          -  Received any investigational drug within 30 days before screening\n\n          -  Participated in any other clinical trial within 30 days before signing informed\n             consent for the current trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116660", 
            "org_study_id": "0518-284", 
            "secondary_id": "2013-001637-40"
        }, 
        "intervention": [
            {
                "arm_group_label": "Raltegravir plus Nevirapine plus Lamivudine", 
                "description": "Raltegravir (MK-0518) 400 mg tablets", 
                "intervention_name": "Raltegravir (MK-0518)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Raltegravir plus Nevirapine plus Lamivudine", 
                "description": "Nevirapine (NVP) 200 mg tablets", 
                "intervention_name": "Nevirapine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Raltegravir plus Nevirapine plus Lamivudine", 
                "description": "Lamivudine (3TC) 150 mg tablets", 
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine", 
                "description": "Tenofovir disoproxil fumarate (TDF) 300 mg tablets", 
                "intervention_name": "Tenofovir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine", 
                "description": "Emtricitabine (FTC) 200 mg tablets", 
                "intervention_name": "Emtricitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine", 
                "description": "Lopinavir (LPV) 200 mg tablets", 
                "intervention_name": "Lopinavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine", 
                "description": "Ritonavir (r) 100 mg tablets", 
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine", 
                "description": "Atazanavir (ATV) 300 mg tablets", 
                "intervention_name": "Atazanavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine", 
                "description": "Darunavir (DAR) 400 mg tablets", 
                "intervention_name": "Darunavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Ritonavir", 
                "Lopinavir", 
                "Atazanavir", 
                "Darunavir", 
                "HIV Protease Inhibitors", 
                "Nevirapine", 
                "Lamivudine", 
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Emtricitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 29, 2014", 
        "number_of_arms": "2", 
        "official_title": "Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study)(Phase 2b - Protocol No. MK-0518-284-01)", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in Renal Function", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 48"
            }, 
            {
                "measure": "Percentage of Participants with Decline in Renal Function at Week 48", 
                "safety_issue": "Yes", 
                "time_frame": "Week 48"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116660"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants with Suppressed Viremia (<50 copies/mL HIV-1 Ribonucleic Acid [RNA]) at Week 48", 
                "safety_issue": "No", 
                "time_frame": "Week 48"
            }, 
            {
                "measure": "Percentage of Participants with Suppressed Viremia (<50 copies/mL HIV-1 RNA) at Week 96", 
                "safety_issue": "No", 
                "time_frame": "Week 96"
            }, 
            {
                "measure": "Percentage of Participants with Decline in Renal Function at Week 96", 
                "safety_issue": "Yes", 
                "time_frame": "Week 96"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}